Compare Globus Medical Inc. Class A Common Stock (GMED) vs Sea Limited (SE) Price & Performance

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

Sea Limited (SE) trades at $95.93, showing minimal daily movement (+0.05%). The stock faces bearish technical signals despite strong fundamentals, with revenue growing from $12.4B in 2022 to $22.9B in 2025 and net income turning positive at $1.58B. Recent earnings show mixed results with Q4 2025 missing expectations but subsequent quarters beating estimates. Analyst sentiment remains strongly bullish with a $153.67 consensus target, representing 60% upside potential from current levels.

The investment case hinges on continued e-commerce and fintech growth execution against competitive pressures. Key risks include margin compression concerns and insider selling activity. With positive cash flow generation established and strong institutional support, the stock presents a compelling growth opportunity despite near-term technical weakness.